Key Takeaway: CG Oncology has announced its participation in various upcoming conferences, including presentations related to the BOND-003 Cohort C and CORE-1008 trials. The company is also involved in promoting research in non-muscle invasive bladder cancer through fellowship awards. Recent results from their trials have been positive, indicating progress in their treatment approaches.
Price reaction · baseline $44.84 (2025-11-28 close) · hit pre-market · 2 other CGON headline(s) in the window, move may be shared
day 0 close · peak
-3.5%
Market Sentiment Analysis
POSITIVE FACTORS
CG Oncology is actively participating in multiple conferences.
The company reported positive results from a recent trial.
They are supporting research through fellowship awards.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer
Full Press Release Details
by admin | Dec 1, 2025 | congress-hub-posters
Recent Posts
• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation
Recent Comments
Frequently Asked Questions
What is the focus of the BOND-003 Cohort C?
The BOND-003 Cohort C focuses on treatments for non-muscle invasive bladder cancer.
What recent results did CG Oncology report?
CG Oncology reported positive results from the CORE-1008 trial evaluating intravesical therapy.
What awards did CG Oncology announce?
CG Oncology announced recipients of the Non-Muscle Invasive Bladder Cancer Research Fellowship.
When is CG Oncology presenting at conferences?
CG Oncology is set to present at various conferences, including SUO 2025.